ATE505464T1 - Feste form von amg 706 und pharmazeutische zusammensetzungen davon - Google Patents

Feste form von amg 706 und pharmazeutische zusammensetzungen davon

Info

Publication number
ATE505464T1
ATE505464T1 AT06849937T AT06849937T ATE505464T1 AT E505464 T1 ATE505464 T1 AT E505464T1 AT 06849937 T AT06849937 T AT 06849937T AT 06849937 T AT06849937 T AT 06849937T AT E505464 T1 ATE505464 T1 AT E505464T1
Authority
AT
Austria
Prior art keywords
amg
amorphous
drug substance
crystallization inhibitor
pharmaceutical compositions
Prior art date
Application number
AT06849937T
Other languages
English (en)
Inventor
Belle B Liu
Gonzalo Alva
Nina Cauchon
Seshadri Neervannan
Pengzu Zhou
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE505464T1 publication Critical patent/ATE505464T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06849937T 2005-12-23 2006-12-08 Feste form von amg 706 und pharmazeutische zusammensetzungen davon ATE505464T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75390905P 2005-12-23 2005-12-23
US11/636,183 US20080108664A1 (en) 2005-12-23 2006-12-07 Solid-state form of AMG 706 and pharmaceutical compositions thereof
PCT/US2006/047238 WO2007087026A2 (en) 2005-12-23 2006-12-08 Solid-state form of amg 706 and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
ATE505464T1 true ATE505464T1 (de) 2011-04-15

Family

ID=38198261

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06849937T ATE505464T1 (de) 2005-12-23 2006-12-08 Feste form von amg 706 und pharmazeutische zusammensetzungen davon

Country Status (8)

Country Link
US (3) US20080108664A1 (de)
EP (1) EP2013198B1 (de)
JP (1) JP5830216B2 (de)
AT (1) ATE505464T1 (de)
AU (1) AU2006336563B2 (de)
CA (1) CA2633077C (de)
DE (1) DE602006021348D1 (de)
WO (1) WO2007087026A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126705A2 (en) * 2008-04-10 2009-10-15 Virginia Commonwealth University Induction of tumor hypoxia for cancer therapy
US20110104161A1 (en) * 2008-05-14 2011-05-05 Burgess Teresa L Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
US20100003319A1 (en) * 2008-07-02 2010-01-07 Glenmark Generics Ltd. Raloxifene immediate release tablets
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
JP5975886B2 (ja) * 2010-03-11 2016-08-23 ヘルス リサーチ インコーポレイテッドＨｅａｌｔｈ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． Ｆｃ融合タンパク質を含む、免疫応答を増強するための方法および組成物
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
WO2016022750A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2011116C (en) 1989-03-06 1999-11-16 Murray A. Kaplan Lyophilized bmy-28142 dihydrochloride for parenteral use
JP2762522B2 (ja) 1989-03-06 1998-06-04 藤沢薬品工業株式会社 血管新生阻害剤
JPH02279769A (ja) * 1989-04-20 1990-11-15 Kao Corp ブリリアントカーミン６ｂナトリウム塩の無定形物、その製造法及びこれを含有する化粧料
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
EP0828495B1 (de) 1995-06-01 2002-10-30 G.D. Searle & Co. Misoprostolhaltige feste stabilisierte dispersionen
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US6582921B2 (en) * 1996-07-29 2003-06-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses thereof
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
WO2000012089A1 (en) 1998-08-31 2000-03-09 Merck & Co., Inc. Novel angiogenesis inhibitors
WO1999045009A1 (en) 1998-03-04 1999-09-10 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
SK287132B6 (sk) 1998-05-29 2009-12-07 Sugen, Inc. Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
EP1097147A4 (de) 1998-07-10 2001-11-21 Merck & Co Inc Neue angiogenese-inhibitoren
BR0009507A (pt) 1999-03-30 2002-01-15 Novartis Ag Derivados de ftalazina para o tratamento de doenças inflamatórias
PT1244647E (pt) 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
AU1928501A (en) 1999-11-24 2001-06-04 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
WO2002059110A1 (en) 2000-12-21 2002-08-01 Glaxo Group Limited Pyrimidineamines as angiogenesis modulators
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
MXPA04008932A (es) 2002-03-15 2004-11-26 Pharmacia Corp Parecoxib sodico cristalino.
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases

Also Published As

Publication number Publication date
WO2007087026A2 (en) 2007-08-02
WO2007087026A3 (en) 2007-09-13
DE602006021348D1 (de) 2011-05-26
US8648199B2 (en) 2014-02-11
US20130317227A1 (en) 2013-11-28
CA2633077A1 (en) 2007-08-02
AU2006336563A1 (en) 2007-08-02
CA2633077C (en) 2012-02-21
AU2006336563B2 (en) 2010-08-26
EP2013198A2 (de) 2009-01-14
US20100331548A1 (en) 2010-12-30
US20080108664A1 (en) 2008-05-08
JP5830216B2 (ja) 2015-12-09
WO2007087026A9 (en) 2009-01-08
EP2013198B1 (de) 2011-04-13
JP2009527460A (ja) 2009-07-30

Similar Documents

Publication Publication Date Title
ATE505464T1 (de) Feste form von amg 706 und pharmazeutische zusammensetzungen davon
DK1150959T3 (da) Faststoftilstandsform af Celecoxib, der har foröget biotilgængelighed
CY1118179T1 (el) Φαρμακευτικη συνθεση
ATE322265T1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
BRPI0507628A (pt) composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
MX344865B (es) Metodos para usar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(met ilamino)-1-pirrolidinil]-4-oxo-1(2-tiazolil)-1,8-naftiridina-3-ca rboxilico para el tratamiento de ciertos padecimientos hematologicos.
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
ME00181B (me) Farmaceutske formulacije inhibitora renin-angiotenzin sistema (ras) i njihova primjena
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
ATE508114T1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
WO2007128086A3 (en) Novel viral replication inhibitor
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
MY128971A (en) Solid-state form of celecoxib having enhanced bioavailability
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
EP1844779A3 (de) Tergurid/Protergurid zur Behandlung von chronischen Schmerzen (z.B. Migräne)
ATE489380T1 (de) Hydratformen von amg706
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
DE60236443D1 (de) Inhibitoren der kostimulation via ox40 und deren verwendung gegen eine von virusen induzierten immunpathologie
EA200901145A1 (ru) Применение рибофлавина в лечении гипертензии
SE0203817D0 (sv) New composition

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties